Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06554301 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

StatusRecruiting
PhasePhase 1
Started2024-10-20
View on ClinicalTrials.gov ↗

Amendment history

2026-03-17
minor
Study Status v3
Primary completion date2025-12→2026-12
2025-11-14
minor
Study Status v2
Re-verified, no change to tracked fields
2025-02-18
notable
Not Yet Recruiting→Recruiting Study Status, Outcome Measures, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-09→confirmed 2024-10-20
Secondary endpointsdetails revised at 5 of 5 entries
Study sitesdetails revised at 1 of 1 site
2024-08-12
minor
Original filing
The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin. The main questions it aims to answer are: Based on standard treatment, does empagliflozin reduce pulmonary artery pressure and improve cardiac function in patients with pulmonary arterial hypertension? What medical problems do participants have when taking empagliflozin? Researchers will compare empagliflozin to a placebo (a look-alike substance that contains no drug) to see if empagliflozin works to treat patients with pulmonary arterial hypertension. Participants will: Take empagliflozin or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the drug taking situation
Trial Details
NCT Number NCT06554301
Lead Sponsor China National Center for Cardiovascular Diseases
Collaborators: The Second Hospital of Shandong University, The First People's Hospital of Changzhou
Conditions Pulmonary Arterial Hypertension
Enrollment 72 participants
Start Date 2024-10-20
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-19